Executive Summary
Incidental interstitial lung abnormalities on pre-TAVR CT scans predict a near-doubling of 3-year mortality, a finding that should reshape how heart teams read the CT they already have in hand. In a 572-patient single-center Bonn cohort published in Heart & Lung, ILA carried an independent HR of 1.59 (95% CI 1.17-2.19) for 3-year all-cause mortality, with 57.6% mortality in ILA patients versus 36.4% without. Reduced FVC only predicted death in the ILA subgroup, suggesting the lung findings and the physiology travel together. Which tightens the case for integrating structured pulmonary review into every TAVR CT read — and complicates the durability calculus for younger low-risk candidates who happen to have subclinical ILD.
- ILA prevalence was 20.8% in a consecutive transfemoral TAVR cohort — high enough that this is not a rare-finding problem (Heart & Lung, retrospective, single-center).
- Diffusion capacity (DLCO 47.4% vs 55.9%) and FVC (65.2% vs 72.0%) were both meaningfully worse in ILA patients, arguing for pre-op PFTs when CT flags ILA (Bonn cohort).
- An ergonomics study of a TAVR instrument platform reduced high-risk neck and torso postures for attendings but increased shoulder loading — a real trade-off for operator longevity (American Journal of Surgery, N=120 cases).
- Medtronic's Intrepid TTVR early feasibility study (NCT04433065, N=150) moved to active/not-recruiting, tightening the timeline to pivotal data readout (ClinicalTrials.gov).
- A new Myval TAVR study in high-risk severe aortic regurgitation was posted (NCT07751965, N=164, not yet recruiting), extending the off-label AR push into prospective territory (ClinicalTrials.gov).
What to watch: Medtronic's fiscal Q1 earnings on September 1 will be the next hard read on structural heart momentum, with Intrepid TTVR feasibility completion sitting behind the number.
Aortic Valve (TAVR/TAVI)
Pre-procedural CT is doing more work than we credit it for, and today's data says we should be reading the lungs as carefully as the annulus. The Bonn group's 572-patient retrospective (transfemoral TAVR, 2018-2021, single-center) identified ILA in 20.8% of scans and tied it to 57.6% 3-year mortality vs 36.4% without — an independent HR of 1.59 after multivariable adjustment. Reduced FVC only mattered prognostically when ILA was present, which suggests the imaging finding and the restrictive physiology are the same disease at different resolutions. The limitations are what you'd expect: retrospective, single-center, no core lab adjudication of ILA. But the effect size is large enough that heart teams shouldn't wait for a multicenter replication to change practice. [NOTABLE] Add pulmonary review to the TAVR CT read.
Surgical counterpoint: current ESC 2025 and ACC/AHA 2020 guidance emphasizes life expectancy >12 months as the threshold for intervening at all in severe AS. Subclinical ILD directly attacks that assumption. For patients under 70 who would otherwise be borderline SAVR candidates under ESC 2025, an ILA finding may push the calculus back toward medical therapy or palliation rather than deeper into transcatheter territory.
Separately, Ceric Sàrl posted a prospective Myval TAVR study for high-risk severe aortic regurgitation (NCT07751965, N=164, not yet recruiting). AR remains a Class IIb TAVI indication in ESC 2025 for inoperable patients only, and every AR-TAVI dataset to date has been retrospective and heterogeneous. A prospective cohort — even non-randomized — would be a step forward.
Tricuspid Valve (TriClip, TTVR)
The Intrepid TTVR early feasibility study (NCT04433065, N=150, Medtronic) moved to active/not-recruiting, which puts complete enrollment behind us and tightens the runway to full feasibility readout. Intrepid is Medtronic's transcatheter tricuspid replacement platform, competing with Edwards' EVOQUE (already approved via TRISCEND II) and Abbott's TriClip repair franchise. ESC 2025 elevated transcatheter tricuspid treatment to Class IIa (LOE A) for high-risk symptomatic severe TR — a threshold ACC/AHA 2020 did not address at all. That guideline gap makes every incremental TTVR safety and efficacy signal disproportionately important for U.S. adoption. Real-world STS/ACC TVT Registry data on EVOQUE showed 98.4% technical success and 3.1% 30-day mortality, but 15.9% new pacemaker rate in CIED-naive patients — a durability question that Intrepid will need to answer on its own terms.
Device & Technology
An overlooked cost of the transcatheter era: the operators. A quaternary-center ergonomics study across 120 TAVR cases (67 baseline, 53 intervention) tested a cardiovascular instrument platform that positions equipment in front of operators rather than requiring them to turn behind. High-risk neck and torso postures fell for attendings; shoulder loading rose. Twelve operators is a small sample and the sex distribution skewed male, but the trade-off is real: you cannot solve one WMSD risk without generating another under lead. The broader point is that structural heart programs are running on a workforce whose career longevity is being quietly eroded by the physical demands of the cath lab. Program directors should be treating operator ergonomics as a capital-allocation decision, not an afterthought.
Surgical vs. Transcatheter Comparisons
No head-to-head comparisons landed today. But the Bonn ILA data reframes the surgical-vs-transcatheter question for a specific slice of patients: those with subclinical ILD detected on the very CT that qualifies them for TAVR. Neither ACC/AHA 2020 nor ESC 2025 explicitly incorporates ILA into risk assessment. STS-PROM and EuroSCORE II under-weight pulmonary disease that isn't clinically declared. For a 68-year-old with ILA and severe symptomatic AS, the ESC 2025 preference for TAVI at ≥70 doesn't cleanly apply, and the 3-year mortality signal argues for a hard conversation about whether any intervention changes the trajectory.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $89.72, +0.45% on the day, +16.82% over 6 months
- Market cap $51.7B, trailing P/E 53.4, forward P/E 26.58, beta 0.85
- 52-week range $72.30 - $96.29
- Analyst consensus target $100.96 (range $84-$110, 26 analysts), Buy
- Next earnings 2026-10-29 (EPS est $0.74, Rev est $1.68B)
Edwards continues to lead the group on 6-month performance, sitting near the top of its 52-week range. The EVOQUE tricuspid franchise plus PASCAL mitral repair is doing the heavy lifting; SAPIEN volumes remain the earnings engine but growth is decelerating as the low-risk population saturates. Any incremental ILA-type risk stratification data that trims TAVR eligibility at the margins is a slow-burn concern, not a near-term thesis threat.
Medtronic (MDT)
- Close $87.16, +1.44% on the day, -12.77% over 6 months
- Trailing P/E 23.37, forward P/E 13.59, beta 0.57
- 52-week range $73.31 - $106.33
- Analyst consensus target $98.44 (range $78-$121, 25 analysts), Buy
- Next earnings 2026-09-01 (EPS est $1.39, Rev est $9.55B)
Six-month underperformance reflects broader diversified-medtech pressure, not structural heart specifically. The Intrepid TTVR feasibility completion is a meaningful catalyst — if the data reads out cleanly, Medtronic gets a credible TTVR platform to challenge EVOQUE. Evolut Low Risk long-term durability data continues to be the swing factor for the TAVR franchise.
Abbott (ABT)
- Close $107.81, -0.14% on the day, -1.63% over 6 months
- Market cap $186.6B, trailing P/E 34.89, forward P/E 17.78, beta 0.58
- 52-week range $81.97 - $137.49
- Analyst consensus target $118.42 (range $103-$135, 24 analysts), Buy
- Next earnings 2026-10-14 (EPS est $1.42, Rev est $12.99B)
Roughly flat over six months. MitraClip and TriClip are the structural heart franchises to watch — the ESC 2025 Class I upgrade for TEER in ventricular secondary MR is a real tailwind that hasn't fully flowed through to volumes. TriClip vs EVOQUE remains the more interesting near-term competitive fight given the ESC 2025 Class IIa transcatheter tricuspid endorsement.
Boston Scientific (BSX)
- Close $49.31, +0.02% on the day, -33.47% over 6 months
- Market cap $71.5B, trailing P/E 19.96, forward P/E 14.34, beta 0.57
- 52-week range $42.20 - $109.50
- Analyst consensus target $62.69 (range $44-$94, 29 analysts), Buy
- Next earnings 2026-10-21 (EPS est $0.81, Rev est $5.26B)
BSX is the group's outlier — a 33% six-month drawdown that reflects broader concerns beyond structural heart, but the ACURATE neo2 withdrawal and stalled Sentinel volumes haven't helped the valve narrative. At the low end of the 52-week range, the setup is now about whether the company can articulate a coherent structural heart strategy without a leading TAVR platform.
Anteris Technologies (AVR.AX)
- Close $12.01 AUD, +3.98% on the day, +54.37% over 6 months
- Market cap $1.2B, forward P/E -5.51 (pre-revenue), beta 0.73
- 52-week range $5.20 - $15.47
- Analyst target $13.00 (1 analyst)
DurAVR continues to be the small-cap TAVR story with genuine differentiation on the biomimetic single-piece leaflet design. Six-month gain of 54% reflects momentum on early clinical data and the potential durability pitch to younger patients — the exact population where the Bonn ILA data cuts against reflexive TAVR expansion. Anteris still has to raise capital and complete pivotal enrollment before this is a real commercial story.
Market outlook: The group is bifurcating. Edwards and Anteris ride positive momentum on differentiated platforms; Medtronic and Boston Scientific are pinned by broader medtech multiples and franchise-specific questions. The next structural heart re-rating catalyst is Medtronic's September 1 print and Intrepid feasibility timing.
Clinical Trial Updates
Aortic
- NCT07751965 — Prospective Multicenter Study Evaluating Myval TAVR Safety and Effectiveness in High-risk Severe AR. Status: Not yet recruiting. Enrollment: 164. Sponsor: Ceric Sàrl. Intervention: Myval THV series. First prospective cohort testing Myval in the AR indication, which remains ESC 2025 Class IIb for inoperable patients only.
Tricuspid Replacement
- NCT04433065 — TTVR Early Feasibility Study. Status: Active, not recruiting (updated). Enrollment: 150. Sponsor: Medtronic Cardiovascular. Intervention: Intrepid TTVR System. Enrollment complete; follow-up readout is the next Medtronic structural heart catalyst behind EVOQUE's real-world data.
What next: Watch for whether TAVR programs begin incorporating structured pulmonary review into their CT protocols — the Bonn signal is strong enough that a multicenter replication effort should be visible within 12 months, and it would meaningfully reshape the low-risk enrollment funnel.